Safety and preliminary efficacy of Alkaline Phosphatase in severely burned patients

Phase 1

Completed

• Conditions: <p>Patients with acute thermal burns of at least 15% TBSA</p>; Severe burns; 10014982

• Registration Number: NL-OMON29043
• Lead Sponsor: Rode Kruis Ziekenhuis

Brief Summary

none

Detailed Description

Not available

Study Timeline

• Last Update Posted: 11 June 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

• partial/full thickness acute thermal burns of at least 15% TBSA • Admission burn ICU • Age =18 • Written informed consent from patient or legal representative

Exclusion Criteria

• Inclusion in another interventional clinical trial • Age < 18 • Age > 80 • Patients who are pregnant or lactating • Patients expected to have fatal disease within 24 hours • Patients who have advanced chronic liver disease confirmed by a Child-Pugh C • Patients who are having an known history of immune system that has been impaired by disease, such as patients with HIV and with a CD4 count of less than 200 cells/mm, neutropenic patients (<0.5 x 109/l) or medical treatment with immunosuppressive effects • Patients with active haematological malignancy

Study & Design

• Study Type: Interventional
• Study Design: Not specified